Aims:
To explore real-world outcomes in a regional setting, assessing 1, 2 and 5-year lung cancer overall survival. Uptake of clinical trials, immunotherapy and targeted therapies were also analysed.
Methods:
Border Medical Oncology and Haematology maintains a real time ICD10 code-based registry of all patients, linked to DOB, diagnosis date and DOD. From this, a retrospective analysis was performed in June 2022, of patients with lung cancer who were diagnosed and managed from January 2015 to June 2021.
Results:
674 patients were included. 362 (53.7%) patients had metastatic disease at diagnosis. The 1, 2 and 5-year survival and the percentage uptake for immunotherapy for all subtypes and stages is shown in Table 1. Corresponding data for patients with metastatic NSCLC is shown in Table 2. Uptake of targeted therapies and clinical trials each year was less than 10%.
Table 1.
|
Year |
N |
1-Year Survival (%) |
2-Year Survival (%) |
5-Year Survival (%) |
1L Immunotherapy (%) |
≥2L Immunotherapy (%) |
|
2015 |
80 |
53.8 |
38.8 |
25 |
7.5 |
11.3 |
|
2016 |
90 |
55.6 |
36.7 |
18.9 |
15.6 |
14.4 |
|
2017 |
127 |
55.9 |
40.2 |
23.6 |
14.2 |
15.0 |
|
2018 |
106 |
56.6 |
38.7 |
|
34.0 |
11.3 |
|
2019 |
118 |
61.9 |
49.2 |
|
38.1 |
5.1 |
|
2020 |
104 |
55.8 |
|
|
44.2 |
0 |
|
2021* |
49 |
61.2 |
|
|
46.9 |
0 |
* 6 months data
Table 2.
|
Year |
N |
1-Year Survival (%) |
2-Year Survival (%) |
5-Year Survival (%) |
1L Immunotherapy (%) |
≥2L Immunotherapy (%) |
|
2015 |
26 |
30.8 |
19.2 |
7.7 |
3.8 |
15.4 |
|
2016 |
35 |
34.3 |
17.1 |
11.4 |
5.7 |
20.0 |
|
2017 |
51 |
35.3 |
23.5 |
11.8 |
11.8 |
31.4 |
|
2018 |
59 |
39.0 |
18.6 |
|
27.1 |
20.3 |
|
2019 |
48 |
58.3 |
43.8 |
|
52.1 |
10.4 |
|
2020 |
44 |
38.6 |
|
|
56.8 |
0 |
|
2021* |
19 |
52.6 |
|
|
73.7 |
0 |
Conclusions:
Immunotherapy is being used by clinicians in a regional setting for lung cancer treatment, and its uptake has paralleled some improvement in 1 and 2-year survival compared to our historical practice data.